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Poly (ADP-ribose) polymerase (PARP) plays a critical role in
responding to DNA damage, by activating DNA repair pathways
responsible for cellular survival. Inhibition of PARP is used to
treat certain solid cancers, such as breast and ovarian cancers.
However, its effectiveness with other solid cancers, such as
esophageal squamous cell carcinoma (ESCC), has not been clari-
fied. We evaluated the effects of PARP inhibition on the survival
of human esophageal cancer cells, with a special focus on the
induction and repair of DNA double-strand breaks. The effects
were monitored by colony formation assays and DNA damage
responses, with immunofluorescence staining of cH2AX and
RAD51. We found that PARP inhibition synergized with cisplatin,
and the cells were highly sensitive, in a similar manner to the
combination of cisplatin and 5-fluorouracil (5-FU). Comparable
increases in RAD51 foci formation were observed after each
combined treatment with cisplatin and either 3-aminobenzamide
(3-AB) or 5-FU in three human esophageal cancer cell lines, TE11,
TE14, and TE15. In addition, decreasing the amount of RAD51 by
RNA interference rendered the TE11 cells even more hypersensi-
tive to these treatments. Our findings suggested that the homol-
ogous recombinational repair pathway may be involved in the
synergism between cisplatin and either 3-AB or 5-FU, and that
3-AB and 5-FU may similarly modify the cisplatin-induced DNA
damage to types requiring the recruitment of RAD51 proteins for
their repair. Understanding these mechanisms could be useful for
improving the clinical outcome of ESCC patients who suffer from
aggressive disease that presently lacks effective treatment
options. (Cancer Sci, doi: 10.1111/cas.12281, 2013)
G enomic integrity is maintained by the close cooperationof several DNA repair pathways. Any failure in these
pathways can lead to unrepaired DNA lesions, which cause
cell-cycle arrest and cell death, either directly or following
DNA replication during the S phase of the cell cycle.(1,2)
Therefore, the therapeutic effects of DNA-damaging agents
may be enhanced by the inhibition of DNA repair. This feature
makes DNA repair mechanisms a promising target for novel
cancer treatment regimens.
In recent years, poly (ADP-ribose) polymerase (PARP)
inhibitors have emerged as a novel class of chemotherapeutic
agents. An abundant nuclear protein that catalyzes the forma-
tion of PAR polymers from NAD+, PARP is attached primarily
to glutamic acid residues on acceptor proteins.(3) It participates
in maintaining genomic integrity, as it is a DNA damage-sens-
ing protein that binds to DNA single-strand breaks (SSBs).(4,5)
In addition, PARP plays a role in restarting stalled replication
forks, by attracting Mre11 to these sites.(6,7) Therefore, the
inhibition of PARP generates DNA damage, and the obstructed
replication forks can be converted to replication-associated
DNA double-strand breaks (DSBs), which lead to cell cycle
arrest and cell death unless they are repaired by the homolo-
gous recombinational repair pathway (HR).(8,9) Recently, the
PARP inhibitors in clinical use have been shown to trap
the PARP1 and PARP2 enzymes at damaged DNA.(10) The
trapped PARP–DNA complexes are more cytotoxic than the
unrepaired SSBs caused by PARP inactivation, as the com-
plexes require other genetic repair pathways, such as postrepli-
cation repair and the Fanconi anemia pathway, in addition to
HR, for their repair.(10)
Double-strand breaks are potentially lethal, and are generally
considered to be the most toxic DNA lesions.(11,12) Direct
DSBs are mainly repaired by the non-homologous end joining
pathway,(13) whereas replication-associated DSBs are repaired
by the HR and related replication repair pathways.(9) The HR
and PARP are intricately linked, because the loss of PARP
results in an increase in the recombinogenic lesions normally
repaired by HR.(14–17) Therefore, tumor cells defective in HR
show extremely high sensitivity to PARP inhibitors.(18–24) In
addition, it was recently reported that PARP inhibition sensi-
tizes even HR-proficient tumor cells to ionizing radiation or
alkylating agents, such as methyl methanesulfonate, when
treated in combination for a short time.(25)
Esophageal squamous cell carcinoma (ESCC) is one of the
most lethal malignant diseases, especially in the USA and
Europe.(26,27) Based on biochemical modulation studies,(28,29)
combined therapy with cisplatin and 5-fluorouracil (5-FU) has
recently shown encouraging results, by exerting a synergistic
cytotoxic effect. However, the clinical outcomes and the overall
survival rates of ESCC patients remain poor.(30) The present
study was carried out to evaluate the effects of PARP inhibition
on the cellular survival and the DNA damage response in human
esophageal cancer cells, with a special focus on DSB induction
and repair. We found that PARP inhibition synergized with
cisplatin, and strongly increased the percentage of cells bearing
nuclear foci of RAD51, a key protein in the HR pathway. This
combined therapy was as efficient as the combined treatment
with cisplatin and 5-FU, as compared to that with each drug
alone. Importantly, RAD51 depletion significantly sensitized the
cells to these combined treatments. Our data suggested that HR
may be involved in the synergism between cisplatin and either a
PARP inhibitor or 5-FU in human esophageal cancer cells. In
addition, the PARP inhibitor and 5-FU may similarly modify
the cisplatin-induced DNA damage to types requiring the
recruitment of RAD51 proteins for their repair.
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Materials and Methods
Cells and chemicals. Three human esophageal cancer cell
lines, TE11, TE14, and TE15, were obtained from the Cell
Resource Center for the Biomedical Research Institute of
Development, Aging, and Cancer (Tohoku University, Sendai,
Japan). Both TE11 and TE14 are moderately differentiated
squamous cell carcinomas, and TE15 is a well-differentiated
squamous cell carcinoma. These cell lines were routinely
grown in RPMI-1640 (Invitrogen, Carlsbad, CA, USA) supple-
mented with 10% FBS, and incubated at 37°C in a humidified
atmosphere of 5% CO2 in air. The PARP inhibitor 3-aminoben-
zamide (3-AB) was obtained from Sigma-Aldrich (#A0788; St.
Louis, MO, USA). Cisplatin (Nippon Kayaku, Tokyo, Japan)
and 5-FU (Kyowa Hakko Kogyo, Tokyo, Japan) were dissolved
in PBS at 1 mM.
Detailed experimental procedures are also provided in the
supplementary experimental procedures (Data S1).
Results
Inhibition of PARP in ESCC cell lines. To examine whether
PARP inhibition could be efficacious in the treatment of
ESCC, we first tested three ESCC cell lines, TE11, TE14, and
TE15, for their sensitivity to PARP inhibition. We confirmed
the inactivation of PARP by a PARP inhibitor, 3-AB, and the
depletion of PARP1 by siRNAs, using immunoblotting analy-
ses (Figs S1,S2A), and then measured the cell viability by a
colony formation assay. This assay showed that 3-AB did not
decrease the viability of these ESCC cells, as compared to the
untreated controls (Fig. 1a).
As PARP inhibition increases the collapse of unresolved
SSBs into DSBs at replication forks,(31,32) we investigated the
induction of DSBs by PARP inhibition in these ESCC cells.
Thus, we carried out immunofluorescence staining for cH2AX,
as a marker of DSBs, after the treatment of the ESCC cell
lines with 3-AB. As a result, mild increases in the percentages
of cH2AX foci-positive cells were observed in all of these
cells after the 3-AB treatment (Figs 1b–d,S3A). As the inhibi-
tion of PARP by 3-AB treatment did not impair the colony
forming activity, most of the DSBs generated by the PARP
inhibition might be exactly repaired, and thus not induce cell
cycle arrest or cell death. This notion was supported by similar
findings obtained by experiments using PARP1-depleted cells
in place of 3-AB treatment (Fig. S2A,B).
Combination of PARP inhibition with cisplatin or 5-FU in ESCC
cell lines. Cisplatin and 5-FU are effective chemotherapeutic
agents used with ESCC patients.(28,29) We wished to examine
whether PARP inhibition acts synergistically with either
cisplatin or 5-FU against esophageal cancer cells. Thus, we
treated TE11, TE14, and TE15 cells with either cisplatin or
5-FU, with or without the inhibition of PARP, and then carried
out a colony formation assay to assess the cellular survival
after these treatments (Fig. S4). The colony assay revealed that
3-AB sensitized all of these cell lines to cisplatin (Fig. 2a).
The synergistic inhibition of cell growth was observed by the
combined treatment of TE11 cells with 5 lM cisplatin and
5 mM 3-AB (Fig. S5, Combination Index = 0.471). In stark
contrast, no synergism between 3-AB and 5-FU was observed
(Fig. 2a).
To explore the reason for this distinct sensitization of cells
to cisplatin and 5-FU by 3-AB, we next studied the levels
of cH2AX focus formation generated by each treatment. The
combined treatment with cisplatin and 3-AB induced signifi-
cantly higher percentages of cH2AX focus formation com-
pared to the single treatment with cisplatin (Figs 2b,c,S3A).
The cH2AX focus formation of TE11 cells peaked at 24 h,
and 60% of cells remained foci-positive even at 48 h after
treatment (Fig. 2d). Combined treatment with 5-FU and 3-
AB induced cH2AX focus formation with similar increases
and kinetics as the single treatment with 5-FU, and it
peaked at 24 h after treatment (Figs 2b,c,e,S3A). Although
the TE15 cells treated with 5-FU and 3-AB showed a lower
percentage of cH2AX foci-positive cells, as compared to the
5-FU single treatment, the average numbers of cH2AX foci
per cell generated by these treatments were similar to those
of the other cell lines (Figs 2b,S3A). Similar findings were
obtained by the depletion of PARP1 using siRNA, instead
of 3-AB treatment (Fig. S2C). Therefore, the significantly
increased induction of DSBs by PARP inhibition could
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Untreated 3-AB Fig. 1. Poly (ADP-ribose) polymerase (PARP)
inhibition by 3-aminobenzamide (3-AB) in human
esophageal cancer cell lines. (a) Survival of TE11,
TE14, and TE15 cells after treatment with 3-AB.
(b) Induction of double-strand breaks, indicating
cH2AX focus formation, at 24 h after PARP
inhibition by 3-AB in TE11, TE14, and TE15 cells.
(c) DNA (blue) and cH2AX foci (red) were visualized
at 24 h after treatment of TE11 cells. Scale
bar = 10 lm. (d) Kinetics of cH2AX foci formation
at the indicated periods up to 48 h, after 3-AB
pretreatment for 48 h. Cells with 10 or more foci
were counted as positive. At least 200 nuclei were
counted for each experiment. The average and SD
from at least three experiments are shown.
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enhance the cytotoxic effects of cisplatin treatment of these
ESCC cells.
Modulation of ESCC cell sensitivity to combined treatment with
cisplatin and 5-FU by PARP inhibition. Having established that
the PARP inhibitor could sensitize ESCC cells to cisplatin, we
next compared the anticancer effects between the combined
treatments with cisplatin ⁄3-AB and cisplatin ⁄5-FU, the most
standard chemotherapy for ESCC. We treated the ESCC cells
with cisplatin and 5-FU in concurrent combinations, and then
measured the cell viability by a colony formation assay. As a
result, all of the ESCC cell lines treated with cisplatin plus
5-FU showed similar high degrees of sensitivity to the
cisplatin plus PARP inhibition (Figs 2a,3a,S2B).
To clarify the reason for the high sensitivity of the ESCC
cells to the combined treatment with cisplatin and 5-FU, we
next carried out an immunofluorescence assay for cH2AX pro-
teins in these cell lines. This assay revealed that the cH2AX
focus formation following the cisplatin plus 5-FU treatment
was quite consistent with that following the cisplatin plus
3-AB treatment (Figs 2b,d,3b,d,S3A). Thus, we hypothesized
that 3-AB and 5-FU might play analogous roles in the
increased numbers of DSBs formed in combination with
cisplatin, resulting in the similar sensitivities of the cells to
combined treatments with cisplatin and either 3-AB or 5-FU.
To confirm our hypothesis, we next investigated the cyto-
toxic effect of the triple combination of 3-AB, cisplatin, and
5-FU against ESCC cells. First, we inhibited PARP by
3-AB or depleted it by siRNAs, and then treated the cells
concurrently with cisplatin and 5-FU. The cellular survival
was confirmed by a colony formation assay. This assay
showed that the triple treatment did not cause a further
decrease in the survival of the cells, as compared to the
combined treatment with cisplatin and either 3-AB or 5-FU
(Figs 2a,3a).
Next, we examined the cH2AX focus formation, to assess
the induction of DSBs by the triple treatment of the ESCC
cells. Immunofluorescence staining analysis of cH2AX
revealed that the level of cH2AX focus formation induced by
the triple treatment was not significantly different from that
induced by the combined treatment with cisplatin and either
3-AB or 5-FU in these cells (Figs 2b–d,3b–d,S3A). Similar
findings were obtained by PARP1 depletion instead of 3-AB
treatment (Fig. S2B,C). Therefore, these findings indirectly
supported our hypothesis that PARP inhibition and 5-FU
increase the sensitivity of ESCC cells to cisplatin, by disturb-
ing the same pathway involving the induction or repair of
DNA damage.
Validation of HR, indicating RAD51 foci formation in ESCC cells.
Poly (ADP-ribose) polymerase inhibition induces DSBs, which
require HR for their repair.(31,32) Thus, we next examined the
involvement of HR after the induction of DSBs by PARP inhi-
bition, to understand the mechanisms underlying the synergism
between cisplatin and either 3-AB or 5-FU in ESCC cells. We
assessed RAD51 focus formation, as a hallmark of ongoing
HR, after treatments with 3-AB, cisplatin, and 5-FU alone and
in combination.
Immunofluorescence staining of RAD51 revealed that the 3-
AB treatment significantly increased the percentage of cells
with RAD51 foci, as compared to the untreated controls
(Figs 4a–c,S3B). As 3-AB did not disturb the colony formation
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Fig. 2. Combination of a poly (ADP-ribose) poly-
merase (PARP) inhibitor 3-aminobenzamide (3-AB)
with cisplatin or 5-fluorouracil (5-FU) in human
esophageal cancer cell lines. (a) Survival of TE11,
TE14, and TE15 cells after treatment with either
5 lM cisplatin for 1 h or 3 lM 5-FU for 24 h, with
or without pretreatment with 3 mM (TE14) or
5 mM (TE11 and TE15) 3-AB for 48 h. (b) Evaluation
of the cH2AX focus formation at 24 h after
treatment of TE11, TE14, and TE15 cells with either
cisplatin or 5-FU, with or without pretreatment
with 3-AB. (c) DNA (blue) and cH2AX foci (red)
were visualized at 24 h after treatment of TE11
cells. Scale bar = 10 lm. (d,e) TE11 cells were
treated with either cisplatin or 5-FU, with or
without pretreatment with 3-AB. Cells with 10 or
more foci were counted as positive. At least 200
nuclei were counted for each experiment. The
average and SD from at least three experiments are
shown.
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Fig. 3. Comparison of standard combined trea-
tments for esophageal squamous cell carcinoma
using cisplatin and 5-fluorouracil (5-FU) with or
without poly (ADP-ribose) polymerase (PARP)
inhibition . (a) Survival of TE11, TE14, and TE15 cells
after concurrent combined treatments with
cisplatin and 5-FU, with or without pretreatment
with 3-aminobenzamide (3-AB). (b) Evaluation of
the cH2AX focus formation at 24 h after combined
treatment of TE11, TE14, and TE15 cells with
cisplatin and 5-FU, with or without a pretreatment
with 3-AB. (c) DNA (blue) and cH2AX foci (red)
were visualized at 24 h after treatment of TE11
cells. Scale bar = 10 lm. (d) TE11 cells were treated
with cisplatin and 5-FU in concurrent combination,
after pretreatment with 3-AB. Cells with 10 or more
foci were counted as positive. At least 200 nuclei
were counted for each experiment. The average
and SD from at least three experiments are shown.
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Fig. 4. Validation of the homologous reco-
mbinational repair pathway in esophageal
squamous cell carcinoma cells, indicating RAD51
focus formation. (a) Evaluation of the RAD51 focus
formation 24 h after treatment of TE11, TE14, and
TE15 cells with cisplatin or 5-fluorouracil (5-FU)
alone and in combination, with or without a
pretreatment with 3-aminobenzamide (3-AB). (b)
Representative images of DNA (blue) and RAD51
foci (green) 24 h after the treatment of TE11 cells.
Scale bar = 10 lm. (c) TE11 cells were treated with
or without 3-AB. (d,e) TE11 cells were treated with
either cisplatin or 5-FU, with or without
pretreatment with 3-AB. (f) TE11 cells were treated
concurrently with cisplatin and 5-FU, after
pretreatment with 5 mM 3-AB for 48 h. Cells with
five or more foci were counted as positive. At least
200 nuclei were counted for each experiment. The
average and SD from three experiments are shown.
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activity of the ESCC cells (Fig. 1a), this finding suggested that
the 3-AB-induced DNA damage might be exactly repaired by
HR.
The treatment of cells with cisplatin or 5-FU alone caused
only a slight increase in the percentage of RAD51 foci-positive
cells up to 48 h after treatment. However, the combined
treatment of these cells with cisplatin and either 3-AB or 5-FU
markedly increased the percentage of cells with RAD51 foci,
which reached a maximum at 24 h after each treatment
(Figs 4,S3B). When used in combination with cisplatin, both
3-AB and 5-FU vigorously promoted the production of DSBs,
which require the recruitment of RAD51 proteins for their
repair in these ESCC cells.
The PARP-inhibited ESCC cells treated with or without
5-FU showed similar levels of RAD51 focus formation after
each treatment (Figs 4a–c,e,S3B). Moreover, the addition of 5-
FU did not change the kinetics of RAD51 focus formation by
the combined treatment with cisplatin and 3-AB (Figs 4a,b,d,f,
S3B). These data suggested that 5-FU might not affect the
RAD51 focus formation induced by 3-AB, with or without
cisplatin, in these ESCC cells. Similar results were obtained
by the depletion of PARP1 in place of 3-AB treatment (Fig.
S2D). Thus, the validation of HR additionally supported our
hypothesis that the enhancement of the anticancer effect of
cisplatin, by either PARP inhibition or 5-FU, might be attrib-
uted to similar mechanisms involving HR repair in ESCC
cells.
Depletion of RAD51 enhances 3-AB- or 5-FU-mediated sensitiza-
tion of ESCC cells to cisplatin. As RAD51 plays crucial and
well-established roles in HR,(33–35) we hypothesized that the
critical role of HR would be the underlying reason for the syn-
ergistic effect of cisplatin and either 3-AB or 5-FU in ESCC
cells. Thus, we examined how RAD51 depletion affected the
sensitivity of TE11 cells to these combined treatments. The
depletion of RAD51 by siRNAs was confirmed by an immuno-
blotting analysis, using anti-RAD51 antibodies (Figs 5a,S6A).
We treated RAD51-knockdown cells with either 3-AB, cis-
platin, and 5-FU alone or in combination, under the same
experimental conditions as described above, and then the cellu-
lar survival was measured by a colony formation assay
(Figs 5b,S6B). As expected, RAD51 depletion caused a drastic
increase in the cellular sensitivity to 3-AB. In contrast, RAD51
knockdown showed neither a synergistic nor an additive effect
on the sensitivity to cisplatin or 5-FU alone (Figs 5b,S6B).
These findings suggested that HR might play a major role in
the repair of DNA damage induced by treatment with 3-AB,
but not with cisplatin or 5-FU alone. In contrast to the
treatment with cisplatin or 5-FU alone, RAD51 repression sig-
nificantly sensitized the TE11 cells to cisplatin in combination
with either 3-AB or 5-FU. Considering our finding that the
addition of 3-AB to treatment with 5-FU or cisplatin ⁄5-FU did
not enhance the cH2AX focus formation (Figs 2b,e,3b,d,S3A),
these data supported our hypothesis that the conversion of
cisplatin-induced DNA damage to the types requiring HR for
their repair could play an important role in TE11 cells
sensitization to cisplatin by both 3-AB and 5-FU.
Discussion
Our data showed that the inhibition of PARP exerts a synergis-
tic tumor-cell killing effect in combination with cisplatin, but
not 5-FU, against three ESCC cell lines, TE11, TE14, and
TE15, by the increased induction of DNA damage requiring
HR for repair. Moreover, in the sensitization of cells to
cisplatin, PARP inhibition by 3-AB and 5-FU may function by
similar mechanisms involving HR.
Poly (ADP-ribose) polymerase inhibitors were originally
developed to selectively target HR-defective cells, and have
been tested as a monotherapy and in combination with an
alkylating agent and cisplatin in patients with certain solid
tumors.(36–39) In this study, 3-AB, as a single agent, had mini-
mal cytotoxic efficacy (Fig. 1a), and only modest increases of
cH2AX and RAD51 focus formation in response to 3-AB were
observed in the ESCC cells, as compared to the untreated con-
trols (Figs 1b,4a). These data indicated that the DSBs induced
by 3-AB may be exactly repaired by HR, and therefore, these
cells are predicted to be proficient in HR repair.(40) Thus, con-
sistent with a previous study,(25) PARP inhibitors, in combina-
tion with certain DNA damaging agents, could be useful in the
treatment of even HR-proficient cancer cells.
Poly (ADP-ribose) polymerase and RAD51 are required to
reactivate replication at stalled DNA forks.(6,7,41,42) Therefore,
the synergism between cisplatin and either 3-AB or 5-FU may
be similarly attributed to the failure of replication reactivation
at stalled replication forks, due to the inhibition of PARP
activity or the incorporation of 5-FU into replicating DNA in
the cisplatin-induced DNA lesions. This failure may lead to
increased RAD51 focus formation, for the efficient restarting
of stalled replication forks by HR. The addition of 3-AB to
either the 5-FU or cisplatin ⁄ 5-FU treatment neither facilitated
nor repressed the cellular survival and cH2AX ⁄RAD51 focus
formation (Figs 2a,b,3a,b,4a), therefore, 3-AB and 5-FU may
function in an epistatic pathway for the cisplatin-induced DNA
lesion repair in ESCC cells. Our results suggested that a novel
regimen, combining cisplatin with a PARP inhibitor, may have
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Fig. 5. Knockdown of RAD51 protein renders esophageal squamous
cell carcinoma TE11 cells hypersensitive to combinations of cisplatin
and either 3-aminobenzamide (3-AB) or 5-fluorouracil (5-FU). (a)
Immunoblotting analysis of RAD51 (top) and a-tubulin (bottom) in
TE11 cells, after RAD51 siRNA or non-targeting (NT) siRNA depletion
for 24 h. (b) Relative survival of TE11 cells treated with 3-AB, cisplatin,
and 5-FU alone and in combination, under the same experimental
conditions after RAD51 siRNA or NT siRNA depletion for 24 h, con-
firmed by colony formation assay. The average and SD from at least
three experiments are shown. Values marked with asterisks are statis-
tically significant, as compared with each control (*P < 0.05).
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similar efficacy to the standard combined chemotherapy of
cisplatin and 5-FU in the treatment of ESCC patients.
In conclusion, we have shown that HR may be involved in
the synergism between cisplatin and either PARP inhibition or
5-FU treatment, in human esophageal cancer cell lines. Our
findings provide a platform for extending the potential use of
PARP inhibitors to ESCC patients. Poly (ADP-ribose)
polymerase inhibitors could be novel combinational counter-
parts of cisplatin in the treatment of ESCC. Moreover, cancer
cells with decreased RAD51 activity, due to mutations or dys-
regulation, would be more sensitive to PARP inhibitors than
the surrounding HR-proficient tissue.(43,44) Therefore, consider-
ing the therapeutic potential of PARP inhibitors in the
treatment of ESCC, such cases would be ideal candidates for
PARP inhibitor therapy, and the side-effects usually seen with
classical cytotoxic anticancer drugs could be minimized.
Although it may be premature to extrapolate our results from
only three cultured cell lines, further investigations of the
mechanisms responsible for the increases of RAD51 foci, in
combination with cisplatin and either PARP inhibition or 5-FU
treatment, in human cancer cells will provide novel insights
into cancer therapies.
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Supporting Information
Additional Supporting Information may be found in the online version of this article:
Fig. S1. Immunoblotting analysis of poly (ADP-ribose) PAR and poly (ADP-ribose) polymerase 1 (PARP1) in esophageal squamous cell carci-
noma TE11 cells after exposure to 3-aminobenzamide (3-AB).
Fig. S2. Treatment of poly (ADP-ribose) polymerase 1 (PARP1)-depleted esophageal squamous cell carcinoma TE11 cells with anticancer drugs.
Fig. S3. Numbers of cH2AX and RAD51 foci per nucleus after treatment with anticancer drugs.
Fig. S4. Time schedule of treatments with anticancer drugs.
Fig. S5. Dose–response analysis of the survival of esophageal squamous cell carcinoma TE11 cells treated with cisplatin and 3-aminobenzamide
(3-AB) in combination.
Fig. S6. Knockdown of RAD51 protein using RAD51 siRNA (#2) also renders TE11 cells hypersensitive to combinations of cisplatin and either
3-aminobenzamide (3-AB) or 5-fluorouracil (5-FU).
Data S1. Supplementary experimental procedures and discussion.
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